Massachusetts Biotechnology Council, Inc. Welcomes Seven New Board Members
Clackson, Garabedian, Guhan, Klug, Loebel, Orloff & Pellini Join Board
April 17, 2015 (CAMBRIDGE, MA) – MassBio elected seven life sciences executives to the organization’s Board of Directors at the MassBio Annual Meeting last month.
Joining the board this year are Timothy P. Clackson, PhD, President of R&D and Chief Scientific Officer at ARIAD Pharmaceuticals; Chris Garabedian, former President & CEO at Sarepta Therapeutics; Sam Guhan, PhD, Vice President of Process and Product Engineering at Amgen; Melissa Bradford Klug, Senior Vice President of Business Development & Strategy at AMAG; Antony Loebel, MD, Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. and Head of Global Clinical Development for Sunovion and Sumitomo Dainippon Pharma Co., Ltd.; John J. Orloff, MD, Global Head of Research and Development at Baxter BioScience; and Michael Pellini, MD, CEO at Foundation Medicine.
“We are thrilled to add the significant breadth and depth of expertise that comes with electing these industry executives to the MassBio Board of Directors,” said MassBio President & CEO Robert K. Coughlin. “We rely on these industry experts on the Board to represent and advocate for life sciences organizations and their needs, as well as the needs of various stakeholders. We appreciate the time they devote to building the Massachusetts supercluster through MassBio.”
Tim Clackson, PhD is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals. During his 20 year career at ARIAD, Dr. Clackson has held a series of increasingly senior positions, including President of R&D since 2010 and CSO since 2003. Prior to ARIAD, he was a postdoctoral fellow at Genentech Inc. Dr. Clackson received his PhD in biology from Cambridge University and his BA in biochemistry from Oxford University.
Chris Garabedian is a biotechnology executive that most recently served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015. Prior to Sarepta, Garabedian served as Vice President of Corporate Strategy for Celgene Corporation and had previously held several senior leadership roles at Gilead Sciences. Garabedian received his BS in marketing from the University of Maryland.
Sam Guhan, PhD is Vice President of Process Development at Amgen and is responsible for Drug Substance activities within the PD organization. He also serves as the Site Head for Amgen Massachusetts (AMA), and oversees all aspects of Site operations management and infrastructure, including staff communication, safety and compliance, as well as Amgen’s community and government relations initiatives. Dr. Guhan joined Amgen in 2003. Prior to Amgen, he was at Pfizer’s BioProcess R&D group. Dr. Guhan served as the Treasurer of the Biotechnology Division of the American Chemical Society, the Board for the Recovery of Biological Products Conference Series, and currently serves on the Governing Council of the Leaders for Global Ops group at MIT. He was awarded the VanLanen award in 2006 by ACS/ BIOT for services to the Division of Biochemical Society. Dr. Guhan holds a PhD in Chemical Engineering from Rensselaer Polytechnic Institute.
Melissa Bradford Klug is Senior Vice President of Business Development & Strategy at AMAG Pharmaceuticals. Prior to joining AMAG in 2014, Klug served as Vice President of Corporate Development at Mallinckrodt Pharmaceuticals and held leadership roles in business development at Baxter International and Eli Lilly and Company. Klug holds a BS in Chemistry from Maryville University and an MBA from DePaul University.
Antony Loebel, MD is Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. and Head of Global Clinical Development for Sunovion and its parent company Sumitomo Dainippon Pharma Co., Ltd. He serves as a member of the Sunovion Executive Leadership Team and Board of Directors, as well as an Executive Officer of Sumitomo Dainippon Pharma. Dr. Loebel, a board-certified psychiatrist and scientist, is a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine and a Fellow of the American Psychiatric Association. He currently serves on the Scientific Leadership Advisory Council of PhRMA.
John J. Orloff, MD is Global Head of Research and Development for Baxter BioScience. Before joining Baxter BioScience in 2014, he spent 6 years at Merck & Co., and ten years at Novartis, where he served as Global Chief Medical Officer for the pharmaceuticals division. This was followed by a brief stint at Merck Serono. Earlier in his career, he built a distinguished academic career in bone metabolism at Yale University. Dr. Orloff graduated from Dartmouth College and received his medical degree from the University of Vermont. He completed an internal medicine residency at the University of Pittsburgh, serving as Chief Medical Resident. This was followed by a fellowship in endocrinology and metabolism at Yale University School of Medicine.
Michael Pellini, MD joined Foundation Medicine as Chief Executive Officer in May 2011. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc. Dr. Pellini is a board member of the Personalized Medicine Coalition. He received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University.
###
About MassBio
www.massbio.org
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing more than 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
Help employers find you! Check out all the jobs and post your resume.
April 17, 2015 (CAMBRIDGE, MA) – MassBio elected seven life sciences executives to the organization’s Board of Directors at the MassBio Annual Meeting last month.
Joining the board this year are Timothy P. Clackson, PhD, President of R&D and Chief Scientific Officer at ARIAD Pharmaceuticals; Chris Garabedian, former President & CEO at Sarepta Therapeutics; Sam Guhan, PhD, Vice President of Process and Product Engineering at Amgen; Melissa Bradford Klug, Senior Vice President of Business Development & Strategy at AMAG; Antony Loebel, MD, Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. and Head of Global Clinical Development for Sunovion and Sumitomo Dainippon Pharma Co., Ltd.; John J. Orloff, MD, Global Head of Research and Development at Baxter BioScience; and Michael Pellini, MD, CEO at Foundation Medicine.
“We are thrilled to add the significant breadth and depth of expertise that comes with electing these industry executives to the MassBio Board of Directors,” said MassBio President & CEO Robert K. Coughlin. “We rely on these industry experts on the Board to represent and advocate for life sciences organizations and their needs, as well as the needs of various stakeholders. We appreciate the time they devote to building the Massachusetts supercluster through MassBio.”
Tim Clackson, PhD is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals. During his 20 year career at ARIAD, Dr. Clackson has held a series of increasingly senior positions, including President of R&D since 2010 and CSO since 2003. Prior to ARIAD, he was a postdoctoral fellow at Genentech Inc. Dr. Clackson received his PhD in biology from Cambridge University and his BA in biochemistry from Oxford University.
Chris Garabedian is a biotechnology executive that most recently served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015. Prior to Sarepta, Garabedian served as Vice President of Corporate Strategy for Celgene Corporation and had previously held several senior leadership roles at Gilead Sciences. Garabedian received his BS in marketing from the University of Maryland.
Sam Guhan, PhD is Vice President of Process Development at Amgen and is responsible for Drug Substance activities within the PD organization. He also serves as the Site Head for Amgen Massachusetts (AMA), and oversees all aspects of Site operations management and infrastructure, including staff communication, safety and compliance, as well as Amgen’s community and government relations initiatives. Dr. Guhan joined Amgen in 2003. Prior to Amgen, he was at Pfizer’s BioProcess R&D group. Dr. Guhan served as the Treasurer of the Biotechnology Division of the American Chemical Society, the Board for the Recovery of Biological Products Conference Series, and currently serves on the Governing Council of the Leaders for Global Ops group at MIT. He was awarded the VanLanen award in 2006 by ACS/ BIOT for services to the Division of Biochemical Society. Dr. Guhan holds a PhD in Chemical Engineering from Rensselaer Polytechnic Institute.
Melissa Bradford Klug is Senior Vice President of Business Development & Strategy at AMAG Pharmaceuticals. Prior to joining AMAG in 2014, Klug served as Vice President of Corporate Development at Mallinckrodt Pharmaceuticals and held leadership roles in business development at Baxter International and Eli Lilly and Company. Klug holds a BS in Chemistry from Maryville University and an MBA from DePaul University.
Antony Loebel, MD is Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. and Head of Global Clinical Development for Sunovion and its parent company Sumitomo Dainippon Pharma Co., Ltd. He serves as a member of the Sunovion Executive Leadership Team and Board of Directors, as well as an Executive Officer of Sumitomo Dainippon Pharma. Dr. Loebel, a board-certified psychiatrist and scientist, is a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine and a Fellow of the American Psychiatric Association. He currently serves on the Scientific Leadership Advisory Council of PhRMA.
John J. Orloff, MD is Global Head of Research and Development for Baxter BioScience. Before joining Baxter BioScience in 2014, he spent 6 years at Merck & Co., and ten years at Novartis, where he served as Global Chief Medical Officer for the pharmaceuticals division. This was followed by a brief stint at Merck Serono. Earlier in his career, he built a distinguished academic career in bone metabolism at Yale University. Dr. Orloff graduated from Dartmouth College and received his medical degree from the University of Vermont. He completed an internal medicine residency at the University of Pittsburgh, serving as Chief Medical Resident. This was followed by a fellowship in endocrinology and metabolism at Yale University School of Medicine.
Michael Pellini, MD joined Foundation Medicine as Chief Executive Officer in May 2011. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc. Dr. Pellini is a board member of the Personalized Medicine Coalition. He received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University.
###
About MassBio
www.massbio.org
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing more than 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
Help employers find you! Check out all the jobs and post your resume.